echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Considering the creation of new drugs in China by international standards

    Considering the creation of new drugs in China by international standards

    • Last Update: 2014-05-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Pharmaceutical Economic News May 27, 2014: China's pharmaceutical market is the world's, and how many of the world's pharmaceutical markets will be China's tomorrow? At the time of global pharmaceutical R & D and M & A, what is the position of China pharmaceutical, which started with generic drugs, to meet the impact of another round, or even break through the encirclement and go to the world market? As a high-tech pharmaceutical industry, the development of new drug R & D depends on the promotion of innovative products The sharp decline in the efficiency of independent innovation has forced multinational pharmaceutical companies to turn around - to use their global resources and information network capabilities to re-establish R & D strategies China has also emerged pioneers and Hengrui and other leading enterprises in the global distribution of innovative drugs But for the majority of local enterprises, it is more realistic to develop R & D strategies according to their own actual situation, following the pace and vision of benchmarking The "outside world" of R & D according to McKinsey data, in the past 20 years, the proportion of R & D investment of the world's top ten pharmaceutical companies in total sales revenue has increased from 10% to 17%, at the same time, the economic return rate of drug R & D has dropped from the previous 15% to 5% With the advent of the global patent cliff, more and more attention has been paid to the discussion of the R & D industry crisis in the pharmaceutical field Of course, this is a gradual process, but the R & D mode of leading multinational pharmaceutical companies has changed quietly Among the top 10 global immune / tumor products and 20 potential products in the middle and late clinical stage newly selected by the famous team Goldman Sachs, 75% of the products are generated through non internal R & D, and cooperative authorization is the main source, while extensive alliances and M & A are also important ways In addition, according to the statistics of Thomson Reuters and other institutions, 63% of the end-stage clinical and listed innovative products owned by multinational companies came from external sources (22% from acquisition, 28% from joint development / joint venture, 13% from authorization), and only 37% from internal sources What is particularly interesting is that among the varieties mentioned above, the initial development is basically some unknown research institutions or small companies On the one hand, in the face of the arrival of a large area of patent cliff, the R & D strategies of multinational companies are changing dramatically, ranking in the top 20 in recent years It is common for many multinational pharmaceutical companies in Europe and the United States to have their R & D centers disbanded or large-scale layoffs It has become a consensus that a large number of them rely on external brain On the other hand, it is a global trend for small and medium-sized pharmaceutical companies, especially start-ups, to replace large multinational pharmaceutical companies as the main force of new drug R & D, and the above-mentioned research varieties of global concern are developed by small companies It is not that the R & D strength of small companies is stronger than that of large multinational pharmaceutical companies, but that the multinational companies have better platforms and capital, through various ways, to achieve a wide range of resource integration Multinational pharmaceutical companies need to screen tens of thousands of projects before they can select several of them, and the projects that have been included in the bag may finally be approved for listing In fact, multinational companies have already adopted such R & D strategies in recent years For example, Lilly company strongly recommended a global R & D platform at various R & D gatherings around the world in recent years This project is only limited to the participation of scientific research universities, scientific research institutions and high-tech biotechnology companies Relevant projects can obtain help from the platform through application, and also include a series of screening components 。 These screening components are all of Lilly's long-term strategic interests in related diseases, including cancer, neurological disorders and metabolic diseases What should China do and what experience can be gained from the above data? It is through the use of various platforms and financial strength to leverage the R & D and innovation capabilities of the whole resource coverage area that many multinational companies have successfully passed the crisis of expiration of several major varieties of patents And such a research and development method is clearly what Chinese enterprises can learn and use It is gratifying to see that the "baijiahui" of Xiansheng pharmaceutical industry is in front of the industry at the right time For the establishment of "baijiahui", Ren Jinsheng, chairman of Xiansheng Pharmaceutical Co., Ltd., explained that although it has developed such heavy new drugs as endu and adexin successively, there are still regrets when summarizing the past research and development mode of Xiansheng, "less than expected" is the most concise evaluation, and the reason why it is less than expected is that the advantages in research and development mode, strategy and mechanism of Xiansheng are not obvious The same thing as others Ren Jinsheng believes that the key to the success of China's innovative drugs is to form differences in major strategies and to be more open According to the official website of Xiansheng pharmaceutical, since October 2013, "baijiahui" has introduced more than 200 projects, of which 174 have completed the evaluation, 11 have completed the in-depth evaluation and due diligence, and entered the fund investment decision-making In addition, three joint ventures have been established and funded, and 11 non investment companies have successfully settled in It is estimated that in 2014, "baijiahui" will introduce more than 500 projects from China, the United States, Europe, Canada, Israel and other countries and regions At last, it will attract at least 200 outstanding experts from all countries in biomedical enterprises or academic institutions, forming the agglomeration effect of innovation and Entrepreneurship of high-end talents In recent years, the global open new drug R & D project that Li Li has devoted a lot of effort to is similar to the pioneer "baijiahui" For large pharmaceutical companies, the construction and operation of projects will make these projects become the largest platform in the world to collect and exchange the latest drug research and development achievements and technologies, and the operation subject is undoubtedly the biggest beneficiary The advantage of open new drug research and development project is that more diverse molecular opportunities can be obtained for characterization disease models and target based biological testing At the same time, potential partners can be identified and established to provide business opportunities to further promote R & D results From the perspective of R & D investment return, Xiansheng or Lilly may obtain the most potential varieties within the platform coverage through the minimum investment, and effectively disperse the risk of new drug R & D as small companies are more flat in management, more efficient in operation and greatly reduced in R & D cost, Xiansheng pharmaceutical will also join hands with Hony investment, Zhixin capital and Fosun Pharmaceutical to establish a foundation, and in the future 3 Raised within 30 years Billion yuan For most of the docking projects, the pioneer pharmaceutical industry does not need to pay too much in the early stage Of course, the product revenue share will be adjusted later, but this does not affect the platform's ability to search for new drugs around the world For small start-ups, they can complete the follow-up development with the help of large pharmaceutical companies' funds and resource channels, which can speed up the process of new drug research and development and avoid some potential risks Risk Observation < new drug research and development should be combined with national conditions When it comes to R & D innovation, no matter Lilly or Xiansheng, the operation and operation of similar project screening platforms need huge global information collection and processing capabilities Lilly company benefits from its global layout, and Xiansheng pharmaceutical industry makes full use of the resources of its overseas listing experience, and also brings a number of investment institutions with pharmaceutical background This kind of resource allocation ability is not simple for a domestic pharmaceutical enterprise to operate In addition, similar models are mainly aimed at innovative drugs On the other hand, it is more practical and efficient for most Chinese local enterprises to do well in the innovation of generic drugs Even the innovation of generic drugs is also one of the directions of most multinational pharmaceutical enterprises For example, in the past two years, many domestic pharmaceutical enterprises have focused on the development of monoclonal antibody drugs Leading enterprises in China, such as Lizhu group, Hualan biology, Huahai pharmaceutical, etc., have invested a lot of funds in R & D companies such as CITIC Guojian, Baitai biology, Shanghai SAIJIN have already listed monoclonal antibody drugs and obtained good market benefits Tao Desheng, the new president of Lizhu group, told reporters that in 2009, Lizhu group put forward a strategic transformation to biopharmaceutical, and at the same time made a fundamental adjustment to the product structure, hoping to build Lizhu into a new biopharmaceutical enterprise through 20 years of efforts At present, there are 7 products under development for Lizhu McAb Recently, Lizhu, together with jiankangyuan, a major shareholder, has completed the capital increase of the second round of McAb company Jiangsu Hengrui is another representative of China's pharmaceutical research and development Although the focus of Hengrui's research and development is gradually changing to innovative drugs, Hengrui is really starting from the innovation of generic drugs Since 2000, Hengrui pharmaceutical has tried to develop jointly with domestic research institutions, industry, University and research institutes, and then cooperated with large international pharmaceutical enterprises, but the results failed to satisfy sun piaoyang, the boss, because either the efficiency of R & D into market products is low, or the core technology is difficult to master In the cooperation with foreign institutions, sun piaoyang's most direct demand at that time was that Hengrui's team must participate in the whole process of R & D and design, and understand the whole process of drug R & D from target determination to compound synthesis It is this idea that makes Hengrui an undoubted leader in pharmaceutical research and development in China Its generic drug varieties are as wonderful as the PK of the original research products in China In addition, on the basis of generic drugs, Hengrui has set up a number of research institutions overseas and gradually developed into innovative drugs Hengrui's development can be called a classic of combination of imitation and creation According to the reporter, China's Zhengda Tianqing, dongyangguang, Qilu pharmaceutical, Lunan pharmaceutical and other enterprises are currently developing a large number of first generic drugs for heavy-duty products whose patents are about to expire According to relevant experts, the future of China's pharmaceutical market is no longer "no innovation."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.